INTRODUCTION {#sec1-1}
============

As a common gram-negative pathogen, the consistent infection of *Helicobacter pylori* (*H. pylori*) has been demonstrated to be closely correlated with chronic gastritis and peptic ulcers, and a strong cause of gastric cancer.\[[@ref1]\] According to previous reports, approximately 80% of gastric cancers and 5.5% of all malignancies could be attributed to *H. pylori* infection.\[[@ref2]\] Thus, the World Health Organization has classified *H. pylori* as one of the class I carcinogens in 1994.\[[@ref3]\] At present, gastric cancer remains one of the most common malignancies and the leading cause of cancer-related deaths.\[[@ref4]\] Unfortunately, the mechanism underlying gastric cancer caused by *H. pylori* infection has not been fully uncovered.

Toll-like receptors (TLRs) are evolutionarily conserved transmembrane proteins that can orchestrate host immune responses targeting pathogens *via* selective recognition of pathogen-associated molecules and mediate pathogen--epithelium interactions.\[[@ref5][@ref6]\] In human beings, researchers have found 10 TLRs that participate in the progress of microbial pathogen recognition and innate immunity initiation.\[[@ref7]\] TLR9 is an endosome-bound, transmembrane receptor that can recognize and target hypo-methylated CpG motifs (being abundant in the DNA of bacteria and viruses).\[[@ref8]\] When infection occurs, the DNA can be released actively, or due to the degradation from invading microbes or injured host cells.\[[@ref9]\] By recognizing these aberrant DNAs, TLR9 is activated and triggers alterations in cellular redox balance, as well as the activation of mitogen-activated protein kinases (MAPKs) and nuclear factor kappa-B. These increase the production of inflammatory mediators, thereby causing a much higher risk for chronic inflammatory diseases and cancer.\[[@ref10]\]

Recently, a large body of evidence indicated that TLRs play an important role in tumorigenesis and metastasis. For example, TLR2 and TLR9 have been proven to be able to promote the migration of breast cancer cells.\[[@ref11][@ref12]\] Moreover, TLR9 signaling could also promote cellular migrative and invasive abilities in prostate cancer and oral cancer.\[[@ref13][@ref14]\]

In gastric cancer, several studies have reported that the upregulation of TLR9 may play a role in the progression of gastric cancer.\[[@ref15][@ref16][@ref17]\] However, there is limited knowledge on the mechanism of the upregulation of TLR9 and the roles of TLR9 in gastric cancer. Thus, the present study aimed to evaluate the influence of *H. pylori* on the expression and functions of TLR9 in gastric cancer.

MATERIALS AND METHODS {#sec1-2}
=====================

Culture and isolation of *Helicobacter pylori* DNA {#sec2-1}
--------------------------------------------------

*H. pylori* 26695 (ATCC) was cultured in Columbia agar (Guangdong Huankai Microbial Technology Co., Ltd.) with the addition of 5% sheep blood (Oxoid). Bacterial cells were cultured in a microaerophilic chamber, containing 10% CO~2~, 5% O~2~, and 85% *N*~2~, at 37°C. After 48-h culture on plates coated with Columbia agar, bacterial cells were carefully washed with phosphate buffer solution (PBS) and collected. Finally, these bacterial cells were centrifugated and resuspended in PBS buffer (pH 7.4) for use on the following experiments. A Wizard genomic DNA purification kit (Promega, Madison, WI, USA) was used to extract the genomic DNA of *H. pylori* 26695. In order to remove the bacterial lipopolysaccharide, the genomic DNA was treated with polymyxin B (Sigma-Aldrich) (5 mg/ml of DNA) for 1 h at room temperature.

Cell culture {#sec2-2}
------------

MKN-45 (an immortalized human gastric cancer cell line) was obtained from the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (Beijing, China). MKN45 cells were cocultured with *H. pylori* or *H. pylori* DNA (5 μg/ml) for 12 h in antibiotics-free RPMI1640 (GIBCO, Grand Island, NY, USA) with the addition of 10% fetal bovine serum (GIBCO). The multiplicity of infection was set as 150:1. Cells were maintained in a humidified atmosphere with 5% CO~2~ at 37°C.

Knockdown of TLR9 in MKN45 cells {#sec2-3}
--------------------------------

Four precursor microRNA (pre-miRNA) sequences targeting TLR9 (Gene Bank accession no. NM_138688) were designed using Internet-based application (Invitrogen, USA; [Table 1](#T1){ref-type="table"}). The double-stranded DNA oligonucleotides encoding these four pre-miRNAs were inserted into the pcDNATM6.2-GW/EmGFP-miR expression vector (Invitrogen) and named as pcDNA-TLR9-miR 1\#, 2\#, 3\#, and 4\#, respectively. The negative control (pcDNA-TLR9-miR-neg) with no TLR9-targeting sequence inserted was constructed. The transient transfection was performed using Lipofectamine 2000 (Invitrogen), according to manufacturer\'s instructions. After 48 h, the efficacy of the transfection was observed using a fluorescent microscope. Then, the mRNA and protein expression of TLR9 were detected using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot.

###### 

MiRNA sequences targeting TLR9

  ------------- ------------------------------------------------------------------
  TLR9-miR-F1   TGCTGAGAACTGTCCTTCAACACCAGGTTTTGGCCACTGACTGACCTGGTGTTAGGACAGTTCT
  TLR9-miR-R1   CCTGAGAACTGTCCTAACACCAGGTCAGTCAGTGGCCAAAACCTGGTGTTGAAGGACAGTTCTC
  TLR9-miR-F2   TGCTGAGAAGATGCCGTGCATGTCCAGTTTTGGCCACTGACTGACTGGACATGCGGCATCTTCT
  TLR9-miR-R2   CCTGAGAAGATGCCGCATGTCCAGTCAGTCAGTGGCCAAAACTGGACATGCACGGCATCTTCTC
  TLR9-miR-F3   TGCTGTAGAGGTCCAGCTTATTGTGGGTTTTGGCCACTGACTGACCCACAATACTGGACCTCTA
  TLR9-miR-R3   CCTGTAGAGGTCCAGTATTGTGGGTCAGTCAGTGGCCAAAACCCACAATAAGCTGGACCTCTAC
  TLR9-miR-F4   TGCTGAAAGAAGGCCAGGTAATTGTCGTTTTGGCCACTGACTGACGACAATTATGGCCTTCTTT
  TLR9-miR-R4   CCTGAAAGAAGGCCATAATTGTCGTCAGTCAGTGGCCAAAACGACAATTACCTGGCCTTCTTTC
  ------------- ------------------------------------------------------------------

Quantitative reverse transcription-polymerase chain reaction {#sec2-4}
------------------------------------------------------------

Total RNA was extracted from MKN45 cells using Trizol reagent (Invitrogen), according to manufacturer\'s instructions. The primer sequences were as follows: TLR9: forward: 5′- CACGAGCACTCATTCACGG-3′, reverse: 5′- GACAAGTCCAGCCAGATCAAA-3′; β-actin (internal control): forward: 5′- GGCACTCTTCCAGCCTTCC-3′, reverse: 5′- GAGCCGCCGATCCACAC-3′. These results were analyzed using the comparative CT (ΔΔCT) method to establish the relative expression curves.

Western blot {#sec2-5}
------------

Total protein was extracted from MKN45 cells using a radio-immunoprecipitation assay lysis buffer (Beyotime Biotechnology, Shanghai, China), and the protein concentrations were determined using a BCA Protein Assay kit (Beyotime). The samples were resolved by 5% sodium dodecyl--sulfate polyacrylamide gel electrophoresis and transferred onto PVDF (polyvinylidene fluoride) membranes (EMD Millipore, Billerica, MA, USA). Then, these membranes were blocked with 5% nonfat milk and reacted with the primary antibody of TLR9 (Abcam, UK) overnight at 4°C. Thereafter, the secondary antibody (Jackson) was added and allowed to further react for 1 h at room temperature. The specific bands were detected using a Tanon-4200 automatic chemiluminescence image analysis system (Tanon, Shanghai, China). The results were analyzed using ImageJ software.

Cell Counting Kit-8 assay {#sec2-6}
-------------------------

Cell proliferation was determined using Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan). In brief, 4 × 10^3^ cells per well were seeded into a 96-well plate (NEST). After 1 h of incubation, 5 μg of DNA was added and cocultured with normal medium for 12 h. Then, 10 μl of the CCK-8 solution was added into each well, and absorbance at 450 nm was measured on a microplate reader (Thermo) after 2 h.

Transwell assay {#sec2-7}
---------------

Cellular migration and invasion were detected using the Transwell system (Corning Incorporated, CA, USA). In brief, after 48 h of posttransfection with miRNA, 600 μl of RPMI 1640 plus 10% FBS was added into the lower chamber. Then, the upper chamber, which was coated with (to measure cellular invasion) or without (to measure cellular migration) a Matrigel layer (BD Biosciences, CA, USA), was added with 100 μl of MKN45 cell suspension (2 × 10^5^ cells/ml, containing *H. pylori* DNA at concentrations of 0 and 5 μg/ml). After 72 h, noninvading cells in the filter were removed. Then, cells on the underside of the filter were fixed with 4% paraformaldehyde for 15 min at room temperature, stained with 1% crystal violet (Genemed, No. GMS10007) for 10 min at room temperature, and photographed. For the quantitative assessment, five visual fields per filter were randomly selected, and the number of invading cells was counted using a microscope. Finally, the number of migrating or invading cells stained with crystal violet was lysated and detected at 570 nm on a plate reader (Thermo).

Statistical analysis {#sec2-8}
--------------------

SPSS software version 19.0 (SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis. All data were expressed as mean ± standard deviation. *t*-Test and analysis of variance were used for comparisons between two groups and multiple groups, respectively. *P* \< 0.05 was considered statistically significant.

RESULTS {#sec1-3}
=======

*H. pylori* DNA increased the expression of TLR9 in MKN45 cells {#sec2-9}
---------------------------------------------------------------

First, the expression of TLR9 in MKN45 cells was investigated using qRT-PCR and Western blot. As shown in the present data, TLR9 was abundantly expressed in MKN45 cells, and the treatment with *H. pylori* significantly increased the level of TLR9 \[[Figure 1](#F1){ref-type="fig"}\]. Since *H. pylori* DNA was reported to be a ligand of TLR9, the effect of *H. pylori* DNA on TLR9 expression was further evaluated. It was found that the 12-h treatment of *H. pylori* DNA notably increased the expression of TLR9 in MKN45 cells \[[Figure 2](#F2){ref-type="fig"}\].

![*Helicobacter pylori* (*H. pylori*) upregulates the expression of TLR9 in MKN45 cells. MKN45 cells were stimulated with *H. pylori* for 12 h at a bacterium-to-cell ratio of 150:1, and the expression of TLR9 was detected using Western blot (a) and qRT-PCR (b). \*\**P* \< 0.01, compared with controls](SJG-25-181-g001){#F1}

![*Helicobacter pylori* (*H. pylori*) DNA increased the expression of TLR9 in MKN45 cells. After culturing with 5 μg/ml of DNA for 12 h, the mRNA (a) and protein (b) expression of TLR9 were significantly upregulated in MKN-45 cells. \*\**P* \< 0.01, compared with that in MKN45 cells treated without DNA](SJG-25-181-g002){#F2}

Identification of specific and efficient miRNA sequences that could silence TLR9 {#sec2-10}
--------------------------------------------------------------------------------

As shown in [Figure 3](#F3){ref-type="fig"}, the DNA sequencing results confirmed the successful insertion of the four pre-miRNA sequences targeting TLR9, and no mutations were detected. At 48 h after transfection, qRT-PCR and Western blot assays were used to validate the knockdown of TLR9. As shown in [Figure 4](#F4){ref-type="fig"}, MKN45 cells transfected with pcDNA-TLR9-miR 2\# had the lowest expression of TLR9.

![The construction of recombinant plasmids containing the miRNA insert fragments targeting TLR9. The DNA sequencing results revealed that the inserts are correct, and no mutation was found in the recombinants](SJG-25-181-g003){#F3}

![Knockdown of TLR9 by the specific miRNA. The silencing effect of TLR9 miRNA was evaluated by RT-PCR (a) and Western blot (b) in MKN-45 cells. Blank: untreated; NC: cells transfected with pcDNA-TLR9-miR-neg with no TLR9-targeting sequences inserted. \*\**P* \< 0.01, compared with the blank group. \**P* \< 0.05](SJG-25-181-g004){#F4}

*H. pylori* DNA enhanced cell proliferation, migration, and invasion by upregulating TLR9 expression {#sec2-11}
----------------------------------------------------------------------------------------------------

The effects of TLR9 silencing on cellular proliferation were first examined. As revealed by the CCK-8 assay, MKN45 cells with TLR9 silencing exhibited significantly less viability, when compared with cells in the control group (*P* \< 0.01, [Figure 5](#F5){ref-type="fig"}). Next, the influence of *H. pylori* DNA on cell proliferation was evaluated, and it was found that *H. pylori* DNA could promote cell proliferation, while MKN45 cells with TLR9 downregulation exhibited a significantly lower viability, when compared to parental cells. Moreover, the Transwell assay revealed that both the migration and invasion of MKN45 cells treated by *H. pylori* DNA significantly increased, when compared with controls (*P* \< 0.01 and *P* \< 0.01; Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). In addition, the effects of TLR9 on tumor migration and invasion were also examined. According to the present data, the migration and invasion of MKN45 cells were markedly impaired following the knockdown of TLR9 \[Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}\]. Collectively, these results indicate that *H. pylori* DNA could enhance proliferation, migration, and invasion by activating TLR9 in human gastric cancer cells.

![The silencing of TLR9 suppressed proliferation, whereas *Helicobacter pylori* (*H. pylori*) DNA induced cell proliferation in MKN45 cells. Cell growth viability was investigated in TLR9-knockdown cells with or without *H. pylori* DNA treatment. \*\**P* \< 0.01, compared with NC;^\#\#^*P*\< 0.01, compared with NC + DNA](SJG-25-181-g005){#F5}

![The silencing of TLR9 inhibits migration, whereas *Helicobacter pylori* (*H. pylori*) DNA promotes cell migration in MKN45 cells. MKN45 cells were transfected with the scrambled miRNA or indicated miRNA and cocultured with DNA, respectively. Cells that migrated into the lower wall were stained and counted under a microscope. For quantitative assessment, the number of migrating cells stained with crystal violet was lysated and detected at 570 nm on a plate reader. \*\**P* \< 0.01, compared with the blank group; ^\#\#^*P* \< 0.01, compared with the NC + DNA group](SJG-25-181-g006){#F6}

![The silencing of TLR9 inhibits invasion, whereas *Helicobacter pylori* (*H. pylori*) DNA promotes cell invasion in MKN45 cells. MKN45 cells were transfected with the scrambled miRNA or indicated miRNA and cocultured with *H. pylori* DNA, respectively. \*\**P* \< 0.01, compared with the blank group; ^\#\#^*P* \< 0.01, compared with the NC + DNA group](SJG-25-181-g007){#F7}

DISCUSSION {#sec1-4}
==========

Recently, growing evidence has revealed that TLR9 plays an important role during the initiation and progression of various cancers, such as breast cancer, prostate cancer, and lung cancer.\[[@ref11][@ref12][@ref13][@ref18]\] At present, little is known about the functions of TLR9 in gastric cancer. Kauppila *et al*.\[[@ref19]\] found that *H. pylori* DNA could promote the invasion in AGS (a human gastric adenocarcinoma cell line) gastric cancer cells, whereas chloroquine (a nonspecific TLR9 inhibitor) could inhibit *H. pylori* DNA-induced invasion. However, these did not directly demonstrate that these effects were TLR9-mediated. Hence, the investigators called for these needs to be further confirmed through the controlled downregulation of TLR9 in other studies. In the present study, it was demonstrated that *H. pylori* infection and *H. pylori* DNA could upregulate the expression of TLR9 and enhance cellular proliferation, migration, and invasion in human gastric cancer cells. Furthermore, the knockdown of TLR9 significantly inhibited cellular proliferation, migration, and invasion. These results strongly propose that TLR9 is involved in the tumorigenesis and progression of gastric cancer.

TLRs have been found to play important roles in host cell responses toward pathogens and result in the increased production of inflammatory mediators, which eventually led to higher risk of chronic inflammatory diseases. As it is known, chronic inflammation plays a crucial role in the development of many human cancers. In previous studies, the positive expression of TLR9 was detected in epithelial cells of the human stomach.\[[@ref16][@ref17][@ref20]\] In addition, TLR9 could recognize the existence of *H. pylori* DNA and induce pro-inflammatory responses.\[[@ref21][@ref22]\] Interestingly, another study reported that interactions between *H. pylori* DNA and TLR9 could significantly enhance the production of interleukin (IL)-8.\[[@ref23]\] Similarly, there is a correlation between IL-8 mRNA expression and the severity of tissue damage in the gastric wall.\[[@ref24]\] Moreover, it was found that the overexpression of IL-8 was associated with the development of gastric cancer.\[[@ref25]\] Recently, substantial evidence has suggested that cyclooxygenase-2 (COX-2) and matrix metalloproteinase (MMP) might serve as downstream targets and regulate cellular migration and invasion in gastric cancer. Chang *et al*. reported that TLR2/TLR9 signaling could activate MAPKs and promote a panel of transcriptional factors to bind with the cAMP response element and activator protein 1 elements within the COX-2 promoter. Then, prostaglandin E2 is released to promote invasion and angiogenesis in gastric cancer.\[[@ref26]\] Kauppila *et al*. reported that the stimulation of TLR9 with its agonist increased the expression of MMP13 in gastric cancer cells.\[[@ref19]\] Consistently, Ilvesaro *et al*. found that TLR9 increased the invasion of human prostate cancer cells via upregulating MMP13.\[[@ref27]\] In the future, we intend to conduct a microarray analysis to further explore the regulation network of *H. pylori* DNA and TLR9 signaling in gastric cancer. We also will use GES (a human immortalized gastric epithelial cell line), AGS, SGC7901 gastric cells, and a xenograft model to strengthen the significance of the present study.

CONCLUSION {#sec1-5}
==========

In conclusion, we demonstrated that *H. pylori* DNA can enhance proliferation, migration and invasion by activating TLR9 in gastric cancer. These findings propose TLR9 as a therapeutic target for gastric cancer. The application of the TLR9 inhibitor or neutralizing antibody may provide an alternative therapy to reduce the development of *H. pylori*-mediated gastric cancer after controlling its targeting, specifically to gastric cancer cells.
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